Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pediatric H5N1 MF59-adjuvanted pandemic influenza vaccine dose-ranging study
2016-001898-32Phase 2Completed
- Sponsor
- CSL Seqirus
- Start
- Nov 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of influenza A (H5N1) monovalent vaccine, adjuvanted in influenza (6 arms), sponsored by CSL Seqirus. Primary endpoint: Primary safety endpoint(s). Started Nov 2016; status: completed.
02
Drugs
influenza A (H5N1) monovalent vaccine, adjuvanted
03
Conditions
influenza
Beyond the preview
Go deeper on 2016-001898-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001898-32.